Surface‐exposed calreticulin (ecto‐CRT) and secreted ATP are crucial damage‐associated molecular patterns (DAMPs) for immunogenic apoptosis. Inducers of immunogenic apoptosis rely on an endoplasmic reticulum (ER)‐based (reactive oxygen species (ROS)‐regulated) pathway for ecto‐CRT induction, but the ATP secretion pathway is unknown. We found that after photodynamic therapy (PDT), which generates ROS‐mediated ER stress, dying cancer cells undergo immunogenic apoptosis characterized by phenotypic maturation (CD80high, CD83high, CD86high, MHC‐IIhigh) and functional stimulation (NOhigh, IL‐10absent, IL‐1βhigh) of dendritic cells as well as induction of a protective antitumour immune response. Intriguingly, early after PDT the cancer cells displayed ecto‐CRT and secreted ATP before exhibiting biochemical signatures of apoptosis, through overlapping PERK‐orchestrated pathways that require a functional secretory pathway and phosphoinositide 3‐kinase (PI3K)‐mediated plasma membrane/extracellular trafficking. Interestingly, eIF2α phosphorylation and caspase‐8 signalling are dispensable for this ecto‐CRT exposure. We also identified LRP1/CD91 as the surface docking site for ecto‐CRT and found that depletion of PERK, PI3K p110α and LRP1 but not caspase‐8 reduced the immunogenicity of the cancer cells. These results unravel a novel PERK‐dependent subroutine for the early and simultaneous emission of two critical DAMPs following ROS‐mediated ER stress.
There is a Have you seen? (March 2012) associated with this Article.
Current anticancer regimens mediate killing of tumour cells mainly by activating apoptosis, an immunosuppressive or even tolerogenic cell death process. However, it has recently emerged that a selected class of cytotoxic agents (e.g., anthracyclines) can cause tumour cells to undergo an immunogenic form of apoptosis and these dying tumour cells can induce an effective antitumour immune response (Locher et al, 2010). Immunogenic apoptosis of cancer cells displays the main biochemical hallmarks of ‘tolerogenic’ apoptosis: phosphatidylserine exposure, caspase activation, and mitochondrial depolarization. However, this type of cell death also seems to have two other important properties: (1) surface exposure or secretion of critical ‘immunogenic signals’ that fall in the category of damage‐associated molecular patterns (DAMPs; Zitvogel et al, 2010a) and (2) the ability to elicit a protective immune response against tumour cells (Obeid et al, 2007; Green et al, 2009; Garg et al, 2010b; Zitvogel et al, 2010b).
Several DAMPs have recently been identified as crucial for immunogenic apoptosis. These include surface calreticulin (ecto‐CRT), surface HSP90 (ecto‐HSP90), and secreted ATP (Spisek et al, 2007; Kepp et al, 2009). Ecto‐CRT has been shown to act primarily as an ‘eat me’ signal (Gardai et al, 2005), presumably essential for priming the innate immune system, since depletion of CRT by siRNA knockdown averts the immunogenicity of cancer cell death (Obeid et al, 2007). Similarly, bortezomib‐induced ecto‐HSP90 exposure is crucial for immunogenic death of tumour cells and their subsequent contact with dendritic cells (DCs; Spisek et al, 2007). On the other hand, secreted ATP acts either as a ‘find me’ signal or as an activator of the NLRP3 inflammasome (Elliott et al, 2009; Ghiringhelli et al, 2009). However, while the signalling pathways governing surface exposure of CRT have been delineated to some extent (Panaretakis et al, 2009), insufficient information exists on the molecular pathway behind ATP secretion. Finally, immunogenic apoptosis is sometimes associated with disappearance of certain surface‐associated molecules, for example CD47, which are referred to as ‘do not eat me’ signals (Chao et al, 2010).
One common feature of all immunogenic apoptosis‐inducing stimuli so far identified is induction of endoplasmic reticulum (ER) stress (Panaretakis et al, 2009; Garg et al, 2010b; Zitvogel et al, 2010b). Importantly, in the case of ecto‐CRT triggered by anthracyclines, both ER stress and reactive oxygen species (ROS) production have been found to be mandatory (Panaretakis et al, 2009). However, anthracyclines suffer from dose‐limiting side effects (Minotti et al, 2004; Vergely et al, 2007). Moreover, ROS production is neither a primary effect of anthracyclines nor predominantly ER directed, which makes the anthracycline‐induced ‘ROS‐based’ ER stress less effective and secondary in nature (Minotti et al, 2004; Vergely et al, 2007).
Thus, we envisaged that one way of improving the immunogenicity of dying cancer cells is by using a therapeutic approach that can generate strong ROS‐dependent ER stress as a primary effect (Garg et al, 2011). We hypothesized that photodynamic therapy (PDT; Agostinis et al, 2011) might fit the criterion of primary ER‐directed ROS production. PDT can induce oxidative stress at certain subcellular sites by activating organelle‐associated photosensitizers (Castano et al, 2006; Buytaert et al, 2007). Once excited by visible light and in the presence of oxygen, photosensitizers can generate organelle‐localized ROS that can cause lethal damage to the cells (Agostinis et al, 2002). Additionally, this ROS‐based anticancer therapy can also cause ‘emission’ of DAMPs and activate the host immune system (Korbelik et al, 2005; Garg et al, 2010a).
To test this hypothesis, we used the ER‐associated photosensitizer, hypericin. When it is activated by light, it causes a ROS‐mediated loss‐of‐function of SERCA2 with consequent disruption of ER‐Ca2+ homeostasis, followed by BAX/BAK‐based mitochondrial apoptosis (Buytaert et al, 2006). This photo‐oxidative ER stress (phox‐ER stress) is accompanied by transcriptional upregulation of components of the unfolded protein response (UPR) and by changes in the expression of various genes coding for immunomodulatory proteins (Buytaert et al, 2008; Garg et al, 2010a).
We report here that phox‐ER stress induces immunogenic apoptosis in treated cancer cells. Early after phox‐ER stress and largely preceding phosphatidylserine externalization, cancer cells mobilize CRT at the surface and secrete ATP through an overlapping PERK‐ and phosphoinositide 3‐kinase (PI3K)‐mediated mechanism, which is dissociated from caspase signalling. Intriguingly, we found that LRP1 is required for the docking of ecto‐CRT.
Phox‐ER stress causes cancer cells to undergo immunogenic apoptosis
At the outset, we decided to investigate whether cancer cells dying in response to phox‐ER stress (Hyp‐PDT based; unless otherwise mentioned) can activate human immature DCs (hu‐iDCs). We used phox‐ER stress (Supplementary Figure S1) mediated apoptosis‐inducing conditions reported in our previous studies (Hendrickx et al, 2003; Buytaert et al, 2006) generating ∼87% of cell death of the human bladder carcinoma T24 cells within 24 h (Supplementary Figure S2). T24 cells subjected to Hyp‐PDT underwent phagocytic interactions with hu‐iDCs (Figure 1A). They were also phagocytosed by Mf4/4 phagocytes preferentially over untreated T24 cells (Supplementary Figure S3). Moreover, these Hyp‐PDT‐treated dying T24 cells induced phenotypic maturation of hu‐iDCs, as indicated by surface upregulation of MHC class II (HLA‐DR) and co‐stimulatory CD80, CD83 and CD86 molecules (Figure 1B; Supplementary Figure S4A and B). The significant surface expression of these molecules was similar to that induced by lipopolysaccharide (LPS), a known pathogen‐associated molecular pattern (PAMP) (Figure 1B; Supplementary Figure S4A and B). In contrast, freeze‐thawed T24 cells undergoing accidental necrosis (AN) did not strongly stimulate DC maturation (Figure 1B; Supplementary Figure S4A and B). These findings rule out the possibility that AN might be responsible for the increased DC maturation seen against phox‐ER stressed cells.
To get further insight into the functional status of DCs, we evaluated the pattern of certain cytokines including the generation of nitric oxide (NO) as a marker for respiratory burst (Stafford et al, 2002). We compared DCs exposed to Hyp‐PDT‐treated T24 cells with those exposed to LPS or T24 cells dying following AN. We found that hu‐iDCs exposed to Hyp‐PDT‐treated cancer cells displayed a distinguished pattern of functional activation characterized by NOhigh, IL‐10absent (Figure 1C and D). This was clearly different from that induced by accidental necrotic cells (NOhigh, IL‐10high) or by LPS (NOlow, IL‐10low) (Figure 1C and D). Interestingly, LPS and especially accidental necrotic cells stimulated the production of IL‐10 (Figure 1D), whereas Hyp‐PDT‐treated cells failed to stimulate the production of this immunosuppressive cytokine (Kim et al, 2006; Zitvogel et al, 2006) by hu‐iDCs.
To investigate the ability of cancer cells undergoing phox‐ER stress to activate the adaptive immune system, we carried out in‐vivo experiments in immunocompetent BALB/c mice. Before initiating the in‐vivo experiments, we optimized the mouse colon carcinoma CT26 cell line for Hyp‐PDT‐induced apoptosis (Supplementary Figure S5) and ER stress (Supplementary Figure S1). As observed previously in other cells (Hendrickx et al, 2003; Buytaert et al, 2006), hypericin colocalized strongly with ER Tracker (Supplementary Figure S5A) and upon light irradiation induced not only appreciable cell killing (Supplementary Figure S5B) but also the main hallmarks of apoptosis, including caspase‐3 and PARP cleavage (Supplementary Figure S5C). Furthermore, the CT26 cells exposed to Hyp‐PDT were preferentially phagocytosed over untreated CT26 cells by murine JAWSII DCs (Supplementary Figure S6). Then, in the in‐vivo study, we immunized BALB/c mice with Hyp‐PDT‐treated dying/dead CT26 cells. As positive and negative controls for immunogenic cell death, respectively, we used CT26 cells treated with the anthracycline, mitoxantrone (MTX) or tunicamycin (TN, an inhibitor of N‐linked glycosylation) (Obeid et al, 2007). The immunized mice were then rechallenged with live CT26 tumour cells. Protection against tumour growth at the rechallenge site was interpreted as a sign of successful priming of the adaptive immune system (Figure 1E). Mice immunized with CT26 cells treated with MTX or Hyp‐PDT showed robust signs of activation of the adaptive immune system: both procedures strongly prevented the tumour growth seen in the non‐immunized mice. By contrast, most of the mice immunized with tunicamycin‐treated CT26 cells experienced tumour growth after rechallenge (Figure 1E), which confirms the poor immunogenic properties of cancer cell death induced by this ER stress agent (Obeid et al, 2007). These data suggest that apoptotic cancer cells dying from phox‐ER stress induced by Hyp‐PDT activate the immune system, which is one of the important properties of immunogenic apoptosis.
Cancer cells exposed to phox‐ER stress surface expose or secrete/release immunogenic DAMPs
We next analysed the surface exposure/release of CRT, secreted ATP and extracellular heat‐shock proteins (i.e., HSP90 and HSP70) following phox‐ER stress using three different Hyp‐PDT doses—low, medium, and high PDT. Moreover, because of the reported effects of anthracyclines, MTX, and doxorubicin (DOXO) on immunogenic cell death (Obeid et al, 2007), we used them throughout the study for comparison.
Ecto‐CRT surface exposure, detected by immunofluorescence staining of T24 cells treated with Hyp‐PDT or MTX, showed the characteristic surface ‘patches’ reported previously (Gardai et al, 2005; Obeid et al, 2007; Figure 2A). Cell surface biotinylation followed by immunoblot analysis of the isolated plasma membrane proteins derived from T24 cancer cells treated with Hyp‐PDT revealed that phox‐ER stress (Supplementary Figure S1) induced enhanced surface exposure of CRT (Figure 2B). This ecto‐CRT preceded apoptosis‐associated phosphatidylserine exposure (Supplementary Figure S2) under plasma membrane non‐permeabilizing conditions (Figure 2C). On‐cell western assay (Gonzalez‐Gronow et al, 2007) confirmed these results (Supplementary Figure S7). In general, Hyp‐PDT was observed to be superior to DOXO and MTX (Figure 2D and E), in terms of mobilizing CRT to the surface of cancer cells. Moreover, ecto‐CRT was detectable as early as 30 min after Hyp‐PDT and increased with time (Figure 2E). The 30‐min threshold is much earlier than reported for anthracyclines (Obeid et al, 2007). This induction of ecto‐CRT by Hyp‐PDT was diminished in the presence of the 1O2 quencher l‐histidine, thus revealing its ROS dependence (Buytaert et al, 2006; Supplementary Figure S8A). In contrast to anthracycline‐induced ecto‐CRT exposure (Panaretakis et al, 2008), ecto‐CRT exposure following Hyp‐PDT was not accompanied by co‐translocation of ERp57 to the surface (Figure 2B).
Likewise ecto‐HSP90, certain ER proteins, such as calnexin (CNX), PERK and BiP were also undetectable on the surface of the cells under the same conditions that efficiently mobilized ecto‐CRT (Supplementary Figure S8B). In addition, several other ER proteins have been reported to undergo translocation to the plasma membrane (Zai et al, 1999; Korbelik et al, 2005; Zhang et al, 2010). Therefore, we used cell surface biotinylation combined with immunoblotting to screen for surface‐translocated proteins containing the KDEL ‘ER retrieval’ signal sequence, in wild‐type (WT) and CRT−/− MEFs. Ecto‐CRT (∼63 kDa) was the only protein with the KDEL sequence recognizable on the surface of Hyp‐PDT‐treated cells (Figure 2F). No KDEL‐containing proteins were found in the plasma membrane fraction of cells lacking CRT (Figure 2F). On the other hand, KDEL sequences of ER resident proteins, such as GRP94, GRP78, ERp72 (ER resident protein 72), and PDI, were identifiable by their molecular weights in the intracellular protein fractions of WT and CRT−/− cells (Figure 2F). Overall, these results indicate that phox‐ER stress does not lead to a general surface scrambling of ER proteins (luminal or membrane associated) but rather to a selective and rapid surface exposure of CRT in pre‐apoptotic conditions.
We next asked whether photo‐oxidative stress mediated by other photosensitizers known to localize to other subcellular sites in addition to the ER were equally capable of surface‐exposing CRT. To this end, we used photofrin (PF‐PDT), a photosensitizer used in the clinic and known to induce phox‐ER stress (Szokalska et al, 2009). Interestingly, while phox‐ER stress mediated by Hyp‐PDT strongly induced ecto‐CRT, it was not so for PF‐PDT (Supplementary Figure S8C) under similar apoptosis‐inducing conditions as reported previously (Szokalska et al, 2009). This difference between Hyp‐PDT and PF‐PDT in ecto‐CRT induction might be due to the more pronounced ER localization of hypericin when compared with photofrin (Buytaert et al, 2007; Szokalska et al, 2009; Luo et al, 2010). These data further underline the importance of a robust ER‐directed oxidative stress in inducing ecto‐CRT.
Next, we addressed the possibility that apart from induction of ecto‐CRT, Hyp‐PDT‐treated T24 cancer cells can secrete ATP into the extracellular environment. Analysis of the conditioned media showed that T24 cancer cells treated with Hyp‐PDT secreted ATP (Figure 3A) under non‐permeabilizing plasma membrane conditions (Figure 2C). Secretion of ATP preceded apoptosis‐associated phosphatidylserine exposure (Supplementary Figure S2) and downregulation of the ‘do not eat me’ signal CD47 (Supplementary Figure S8D). Interestingly, at least at medium Hyp‐PDT dose, the corresponding intracellular ATP content rose considerably in the pre‐apoptotic stages (Figure 3B).
It has been shown that extracellular ATP can activate NLRP3‐dependent IL‐1β production by DCs (Ghiringhelli et al, 2009). Hence, we quantified IL‐1β secretion in the co‐incubation conditioned media used in the DC maturation analysis experiments. We found that the hu‐iDCs released significant amounts of IL‐1β when exposed to accidental necrotic T24 cells or those treated with Hyp‐PDT, and in greater amounts than that released against untreated T24 cells or after LPS treatment (Figure 3C). This further substantiates the possibility of inducing immunogenic cancer cell death by phox‐ER stress. Moreover, we also detected passive extracellular release of CRT, HSP90, and HSP70 (Figure 3D) in the conditioned media of late apoptotic cancer cells.
These data together indicate that phox‐ER stress induced by Hyp‐PDT in cancer cells causes an early induction of ecto‐CRT and active secretion of ATP in stressed cells, followed by late apoptotic passive release of HSPs such as HSP70 and HSP90. Thus, from the data presented in this and the previous section, we conclude that phox‐ER stress can induce immunogenic apoptosis in cancer cells.
Ecto‐CRT induction and ATP secretion follow overlapping trails consisting of a secretory pathway and PI3K‐dependent plasma membrane/extracellular trafficking
DAMPs observed in the current study reached the extracellular space actively, thereby implying a possible role for active transport mechanisms like the secretory pathway in their emission. For investigating this plausibility, we used several well‐established small molecule inhibitors that affect the (early biosynthetic and/or distal) secretory pathway.
Inhibition of microtubule‐dependent retrograde transport with nocodazole did not affect ecto‐CRT induction (Supplementary Figure S9A). However, inhibition of ER‐to‐Golgi transport (i.e., early biosynthetic pathway) with brefeldin A (BFA) reduced ecto‐CRT induction in cancer cells treated with anthracyclines or Hyp‐PDT (Figure 4A and B). Furthermore, the translocation of CRT was found to be actin dependent because latrunculin B, an actin inhibitor, reduced ecto‐CRT induction in treated cancer cells (Supplementary Figure S9B). Intriguingly, BFA also reduced the ability of cancer cells to secrete ATP after Hyp‐PDT treatment (Figure 4C). The intracellular levels of ATP were not affected significantly by the presence of BFA (data not shown). This observation also points to ER and Golgi as possible sources for the ATP actively secreted after Hyp‐PDT. Thus, these data suggest that both CRT and ATP follow ER‐to‐Golgi transport pathway to reach the plasma membrane or be secreted.
In the distal secretory pathway, PI3Ks have been reported to modulate the plasma membrane trafficking and mediate exocytotic/secretory processes which are wortmannin sensitive (Campos‐Toimil et al, 2002; Safaei et al, 2005; Abe et al, 2009; Low et al, 2010). Inhibition of secretion/plasma membrane trafficking by wortmannin (Wilson and Guild, 2001; Cousin et al, 2003; Laurino et al, 2005) reduced ecto‐CRT in cancer cells treated with anthracyclines or Hyp‐PDT (Figure 4D and E). In fact, Hyp‐PDT‐induced secretion of ATP was also found to be sensitive to wortmannin‐based inhibition (Figure 4F), whereas wortmannin did not affect the intracellular ATP levels (data not shown). Since, wortmannin tends to exhibit a high affinity for the p110α domain of the PI3K protein (Campos‐Toimil et al, 2002; Yuan and Cantley, 2008) we used a small hairpin RNA (shRNA) to stably deplete the PI3K p110α protein in CT26 cancer cells (Supplementary Figure S9C) in order to confirm the specific involvement of PI3Ks in plasma membrane/extracellular trafficking of CRT and ATP. Knockdown of PI3K p110α significantly attenuated ecto‐CRT induction, after both anthracyclines and Hyp‐PDT treatment (Figure 4G), as well as ATP secretion after Hyp‐PDT treatment (Figure 4H) in cancer cells.
Thus, we conclude that in response to phox‐ER stress, CRT and ATP reach the extracellular space by following overlapping molecular pathways consisting of the classical secretory pathway and PI3K‐dependent (wortmannin inhibitable) plasma membrane/extracellular trafficking.
Cells subjected to phox‐ER stress display ecto‐CRT and secrete ATP through a common molecular pathway requiring PERK
ER stress‐associated molecular mechanisms behind pre‐apoptotic ecto‐CRT induction, which we will refer to as the ‘canonical CRT pathway’, were recently scrutinized for anthracycline‐based immunogenic cell death. The pathways involved were mainly governed by PERK‐mediated S51 eIF2α phosphorylation, ER‐proximal caspase‐8 activation, BAX/BAK and ER‐Ca2+ depletion (Panaretakis et al, 2009). Therefore, we evaluated the relevance of these molecular components in the induction of ecto‐CRT by phox‐ER stress and used anthracyclines (MTX or DOXO) as a reference for ‘canonical CRT pathway’ inducers.
Hyp‐PDT was capable of inducing early eIF2α phosphorylation and late CHOP induction, which indicates that functional activation of the UPR (Supplementary Figure S1) was taking place (Buytaert et al, 2008). Cells lacking PERK were incapable of exposing ecto‐CRT after Hyp‐PDT or anthracyclines treatment (Figure 5A). Moreover, shRNA‐based stable knockdown of PERK in CT26 cancer cells (Supplementary Figure S10A) also reduced ecto‐CRT (Figure 5B). These results highlight the crucial role of PERK in mediating ecto‐CRT induction. In agreement with previous work (Panaretakis et al, 2009), cells in which the WT eIF2α was replaced heterozygously with a non‐phosphorylable S51A mutant failed to induce ecto‐CRT in response to anthracyclines treatment, but Hyp‐PDT‐induced ecto‐CRT was not affected (Figure 5C). Moreover, we observed that cells lacking PERK (Figure 5D) as well as cancer cells with depleted PERK (Figure 5E) failed to secrete ATP following Hyp‐PDT treatment (whereas in both cases, the intracellular ATP content was not affected (data not shown)). Interestingly, it has been recently reported that PERK might play a crucial role in proper secretory pathway functioning (Gupta et al, 2010; Teske et al, 2011). Since, following phox‐ER stress, both ecto‐CRT (Figure 4B) and secreted ATP (Figure 4C) were reduced by defects in the secretory pathway we wondered whether ablation of PERK affected the cell's ability to maintain a proper secretory protein load. Interestingly, we observed that following Hyp‐PDT, while PERK competent cells were able to efficiently modulate their total extracellular secretory protein content (Supplementary Figure S10B and C) cells lacking PERK (Supplementary Figure S10B) or cancer cells with depleted PERK (Supplementary Figure S10C) exhibited difficulties in maintaining corresponding levels of total extracellular secretory protein content. Thus, under phox‐ER stress, PERK might help in proper maintenance of extracellular secretory protein load.
Next, to address the involvement of ER‐proximal caspases in CRT surface translocation, we used zVAD‐fmk, a pan‐caspase inhibitor. We found that zVAD‐fmk strongly suppressed anthracycline‐induced ecto‐CRT in cancer cells (Figure 6A), but it did not affect ecto‐CRT induction following Hyp‐PDT (Figure 6A). Similar effects were also observed in HeLa cells (Figure 6B). These observations suggest that ecto‐CRT induced by phox‐ER stress is caspase independent. In line with these findings, ecto‐CRT induction by Hyp‐PDT was not diminished in cells overexpressing the cytokine response modifier A (CrmA) protein, an inhibitor of caspase‐1 and caspase‐8 (Rodriguez et al, 2003); whereas ecto‐CRT induction by anthracyclines was suppressed (Figure 6B). Moreover, shRNA‐based stable depletion of caspase‐8 in CT26 cancer cells (Supplementary Figure S11A) abolished anthracycline‐induced ecto‐CRT without affecting Hyp‐PDT‐induced ecto‐CRT (Figure 6C). Thus, while caspase‐8 is involved in the canonical CRT pathway as reported previously (Panaretakis et al, 2009), it is dispensable for induction of ecto‐CRT by phox‐ER stress.
On the other hand, while cells lacking BAX/BAK showed a compromised ability to surface expose CRT in response to both anthracyclines and Hyp‐PDT (Figure 6D); yet, they did not show any defect in secretion of ATP following Hyp‐PDT (Figure 6E). The intracellular levels of ATP were not affected by the absence of BAX/BAK (data not shown). For cells lacking BAX/BAK, it has been suggested that their reduced steady‐state levels of ER‐Ca2+ (Scorrano et al, 2003) might play an important role in ecto‐CRT induction (Tufi et al, 2008; Panaretakis et al, 2009). Hyp‐PDT has been observed to induce rapid ER‐Ca2+ depletion, which causes a rise in [Ca2+]Cyt (Buytaert et al, 2006); however, chelation of cytosolic Ca2+ with BAPTA‐AM did not affect the surface mobilization of CRT induced by Hyp‐PDT (Supplementary Figure S11B). Moreover, overexpressing SERCA2 in cells lacking BAX/BAK (DKO/SERCA↑ cells) could not restore their ability to induce ecto‐CRT (Supplementary Figure S11C). Here, SERCA2 overexpression is supposed to correct the low resting [Ca2+]ER in cells lacking BAX/BAK (Scorrano et al, 2003). Thus, we can assume that [Ca2+]Cyt does not govern ecto‐CRT induction after exposure to phox‐ER stress, and that SERCA2 overexpression in cells lacking BAX/BAK does not restore ecto‐CRT.
Based on these observations, we conclude that induction of ecto‐CRT by phox‐ER stress follows a molecular pathway orchestrated chiefly by PERK and BAX/BAK, and that this pathway does not require caspases, eIF2α phosphorylation or increased [Ca2+]Cyt. On the other hand, following phox‐ER stress, ATP is secreted independently of BAX/BAK in a PERK‐dependent manner.
Ecto‐CRT docks on the surface of ER‐stressed cells predominantly via LRP1
The identity of the biological entity/surface receptor that docks ecto‐CRT is unknown (Zitvogel et al, 2010b). Ecto‐CRT colocalizes at least partly with plasma membrane regions rich in GM‐1 gangliosides (Gardai et al, 2005); hence, we hypothesized that ecto‐CRT might bind to the lipid rafts. Since cholesterol is crucial for the stability of lipid rafts we used a cholesterol‐depleting agent, methyl‐β‐cyclodextrin (MBC), to study the surface translocation of CRT in treated cells (Nyasae et al, 2003; Lancaster and Febbraio, 2005). MBC‐based destabilization of lipid rafts resulted in decreased MTX‐induced ecto‐CRT. In contrast, Hyp‐PDT‐induced ecto‐CRT was increased to a certain extent (Figure 7A). These results indicate that correct organization of lipid rafts is not necessary for phox‐ER stress‐induced ecto‐CRT.
To identify the surface receptor for ecto‐CRT, we performed an in‐silico search for candidate molecules. We assumed that a candidate receptor would have two properties: (i) it is a common surface protein in at least human and mouse and (ii) it has a higher affinity for ecto‐CRT than for other major KDEL‐containing ER proteins. The in‐silico approach consisted of functional predictions (protein–protein binding) derived from protein network analysis carried out by using the STRING (Search Tool for the Retrieval of Interacting Genes/Proteins) database and web‐tool available at http://string-db.org/ (Jensen et al, 2009). Analysis of the overall binding interaction networks for both human (Supplementary Figure S12A) and murine CRT (Supplementary Figure S12B) identified low‐density lipoprotein receptor‐related protein 1 (LRP1 or CD91) as a potential candidate receptor. Consequently, to look for a competitive protein–protein interaction network for LRP1 and KDEL‐containing proteins, we assembled the human (Supplementary Figure S12C) and the murine LRP1 (Supplementary Figure S12D) into separate networks with the respective major KDEL‐containing ER proteins, including PDI, ERp72, CRT, ERp57, Bip/GRP78, HSP47, GRP94, P4HB, RCN1, and RCN2. This analysis revealed that CRT is one of the KDEL‐containing proteins with which LRP1 consistently interacts in both human and mouse, in silico.
To translate these in‐silico results into in‐vitro setting, we used cells that are LRP1 competent (LRP1+/+ MEF) or either partially (LRP1+/− MEF) or completely LRP1 deficient (LRP1−/− MEF) (Willnow and Herz, 1994; Roebroek et al, 2006). We treated these cells with Hyp‐PDT or MTX and analysed the levels of ecto‐CRT as well as ‘secreted’ or exo‐CRT. These studies revealed that cells lacking LRP1 display low levels of ecto‐CRT following MTX or Hyp‐PDT treatment (Figure 7B). Correspondingly, the amounts of secreted CRT (or exo‐CRT) increased in these treated cells lacking LRP1 (Figure 7C) in the absence of plasma membrane permeabilization (data not shown). Interestingly, we observed that while untreated and MTX‐treated cells maintained a steady‐state level of secreted CRT in WT conditions, yet Hyp‐PDT‐treated cells reduced the detectable levels of secreted CRT (Figure 7C). It is worth mentioning here that the presence of secreted CRT in untreated conditions is well documented (Patel et al, 1999). Moreover, the presence or absence of secreted CRT tends to vary from one ER stressor to another (Peters and Raghavan, 2011). Specifically in case of Hyp‐PDT, not just the overall secreted CRT content but also the total extracellular secretory protein content was reduced considerably (data not shown), thereby pointing towards a (as yet unexplained) general decrease in ‘secreted proteins’ after low‐dose Hyp‐PDT.
Kinetically, a decrease in LRP1 levels reduced overall ecto‐CRT, while increasing its active secretion (exo‐CRT) after MTX (Figure 7E) or Hyp‐PDT treatment (Figure 7F). Likewise, shRNA‐based knockdown of LRP1 in CT26 cancer cells (Supplementary Figure S13A) suppressed the surface exposure of CRT (Figure 7G). Moreover, decrease in ecto‐CRT was also observed in LRP1‐deficient CHO cells (Supplementary Figure S13B and C), while LRP1 reconstitution (Supplementary Figure S13B) restored ecto‐CRT (Supplementary Figure S13C). Coincidently, this reconstitution was accompanied by slight LRP1 overexpression (Supplementary Figure S13B), which interestingly correlated with overall increase in ecto‐CRT as compared with the WT LRP1 CHO cells (Supplementary Figure S13C). Thus, we can conclude that LRP1‐rich areas are predominant surface docking sites for ecto‐CRT, at least after phox‐ER stress.
Depletion of PERK, PI3K p110α, and LRP1 but not caspase‐8 reduces immunogenicity of phox‐ER stressed dead/dying cancer cells
The in‐vitro data discussed above indicate that for phox‐ER stress‐induced ecto‐CRT, caspase‐8 is dispensable but PERK, PI3K p110α, and LRP1 are crucial at various levels (Figure 8A). In fact, PERK and PI3K p110α were also found to be required for active ATP secretion (Figure 8A). In light of these in‐vitro observations, we hypothesized that PERK, PI3K p110α, and LRP1 but not caspase‐8 might be crucial for the immunogenicity of phox‐ER stressed cancer cells. To verify this hypothesis in vivo, we decided to take advantage of the CT26 mice immunization model (Figure 1E; Supplementary Figure S5). Mice immunized with Hyp‐PDT‐treated CO‐shRNA CT26 cells were highly efficient in resisting tumour growth at the rechallenge sites injected with live, untreated CT26 cells as opposed to non‐immunized CNTR mice (Figure 8B). This is a sign of high immunogenicity leading to the activation of the adaptive immune system as observed for the WT CT26 cells (Figure 1G). In line with the in‐vitro observations, when immunization was carried out with Hyp‐PDT‐treated CT26 cells stably expressing the caspase‐8 shRNA, the immunogenicity of these treated cells was not compromised (Figure 8B). In contrast, mice immunized with Hyp‐PDT‐treated CT26 cells stably expressing shRNA against either PERK, PI3K p110α, or LRP1 showed attenuated resistance to tumour growth at the rechallenge site, thereby pointing towards reduced immunogenicity of these dead/dying CT26 cells (Figure 8B). Depletion of PERK and PI3K p110α impaired immunogenicity of phox‐ER stressed dying/dead CT26 cells to a relatively larger extent than LRP1 depletion. Overall, based on these results we can conclude that PERK, PI3K p110α and to some extent LRP1 are crucial while caspase‐8 is dispensable for mediating phox‐ER stress‐induced immunogenicity of dying/dead cancer cells.
In the current study, we observed that cell death induced by phox‐ER stress endows tumour cells with the major properties of immunogenic apoptosis, including: induction of ecto‐CRT, active secretion of ATP, phenotypic maturation (CD80high, CD83high, CD86high, MHC‐IIhigh), and functional stimulation (NOhigh, IL‐10absent, IL‐1βhigh) of DCs as well as activation of the adaptive immune system, in vivo.
Surface‐exposed CRT was induced by phox‐ER stress before biochemical signs of apoptosis became apparent and in that it resembled ecto‐CRT induction described for anthracyclines (Panaretakis et al, 2009). The anthracycline‐induced ecto‐CRT translocation pathway has been shown to depend on PERK‐mediated eIF2α phosphorylation (eIF2α‐P), followed by caspase‐8‐mediated BAP31‐dependent activation of BAX/BAK proteins (Panaretakis et al, 2009). However, we observed that the pathway governing ecto‐CRT induction by phox‐ER stress differed markedly from the ‘canonical CRT pathway’, as only PERK and BAX/BAK were required for it (Supplementary Figure S14). The apparent dispensability of eIF2α‐P and caspase‐8, or of caspase signalling in general, indicates that ecto‐CRT induction by phox‐ER stress is orchestrated by a different pathway. In fact, these observations downplay the role of UPR signalling as well as ER‐proximal partial caspase activation during phox‐ER stress. We further explored the mechanism of ecto‐CRT exposure and found that for anthracyclines and phox‐ER stress, the classical secretory pathway and PI3 kinase‐dependent plasma membrane trafficking was involved in ecto‐CRT translocation (Supplementary Figure S14). Interestingly, SNARE‐based exocytosis has also been implicated in the canonical CRT pathway thereby substantiating the role of plasma membrane trafficking in this process (Panaretakis et al, 2009). Additionally, we found that the KDEL sequence of ecto‐CRT is not proteolytically removed (Krysko and Vandenabeele, 2008) but is carried with it onto the surface, and that ERp57 is not found ‘complexed’ with ecto‐CRT as has been reported for the anthracycline‐mediated translocation pathway (Obeid et al, 2007; Panaretakis et al, 2009). Intriguingly, this study also sheds new light on the elusive mechanism of surface tethering of CRT (Supplementary Figure S14). We show that LRP1‐deficient/depleted cells have impaired ability to properly dock CRT on their surface and that this defect is independent from the stress‐specific translocation pathway.
Furthermore, we characterized the molecular mechanisms underlying the secretion of another crucial DAMP, secreted ATP, for which no clear‐cut pre‐apoptotic mechanism has been proposed yet (Aymeric et al, 2010). Previously, secreted ATP has been mostly associated with mechanical/osmotic strain (Nandigama et al, 2006), cells in early apoptotic stages, during which caspases are active (Elliott et al, 2009; Chekeni et al, 2010) or in mid apoptotic stages, coincident with nuclear fragmentation (Ghiringhelli et al, 2009; Martins et al, 2009).
We report for the first time that ATP is secreted by stressed cells at a stage that can be considered clearly pre‐apoptotic. We also observed that the concentration of this secreted ATP after phox‐ER stress differed from one cell type to another. Importantly, we also show that induction of ATP secretion by phox‐ER stress is dependent on PERK but independent of BAX/BAK (Supplementary Figure S14). Furthermore, this process of ATP secretion also involves the secretory pathway and PI3 kinase‐dependent extracellular trafficking (Supplementary Figure S14), which makes this pathway different from the ATP secretion pathway instigated during the early apoptotic stage (Chekeni et al, 2010). This also points to ER/Golgi as the possible sources of secreted ATP. Interestingly, we observed that following phox‐ER stress, intracellular ATP levels are increased in the pre‐apoptotic stage, as reported for certain other apoptotic stimuli (Zamaraeva et al, 2005). We suspect that this could be due to the increased ER‐mitochondrial coupling following ER stress favouring the enhanced uptake of Ca2+ by the mitochondria (Bravo et al, 2011), a phenomenon that we also observe following phox‐ER stress (Verfaillie et al, unpublished data). Thus, after phox‐ER stress, both DAMPs (ecto‐CRT and secreted ATP) follow overlapping pathways to reach the extracellular space (Supplementary Figure S14). These overlapping paths are probably part of a specific danger‐signalling system that acts well before signs of apoptosis become manifested. Moreover, it should also be noted that while ecto‐CRT induction (Obeid et al, 2007; Panaretakis et al, 2009) and optimal ATP secretion (Martins et al, 2009) require different doses of anthracyclines, in the case of Hyp‐PDT they are dose associated (i.e., induced by similar doses), thereby integrating the emergence of these two critical immunogenic signals within a single therapeutic set‐up.
Interestingly, we observed that absence or depletion of PERK compromised the ability of phox‐ER stressed cells to modulate their extracellular secretory protein content. This along with the emerging evidence of PERK's role in proper secretory pathway functioning (Gupta et al, 2010; Teske et al, 2011) might imply that PERK could be regulating ecto‐CRT induction and ATP secretion by governing the proper functioning of the secretory pathway after phox‐ER stress; a premise that warrants systematic investigation in the near future. On the other hand, the role of BAX/BAK proteins in ecto‐CRT induction is less clear. A recent study has shown that these pro‐apoptotic proteins regulate ER membrane permeability in ER‐stressed cells (Wang et al, 2011b). Modulation of ER membrane permeability could expedite or assist in the delivery of ER luminal proteins, such as CRT, to the cell surface. However, more research is required to ascertain the link between BAX/BAK and phox‐ER stress‐induced ecto‐CRT.
The depletion of PERK, PI3K p110α, and LRP1 (to a relatively lesser extent) reduced the immunogenicity of phox‐ER‐stressed cancer cells in vivo. The milder effect of LRP1 depletion on immunogenicity could probably be explained by the fact that even extracellularly secreted, non‐surface tethered form of CRT can mediate DC maturation (Bajor et al, 2011) and antitumour immunity (Wang et al, 2011a). However, in contrast to previous observations for anthracyclines (Panaretakis et al, 2009), depletion of caspase‐8 had no effect on phox‐ER stress‐induced immunogenicity. These in‐vivo observations further reinforce the novel molecular pathway observed for phox‐ER stress‐induced ecto‐CRT, in vitro. Importantly, depletion of PERK, PI3K p110α, and LRP1 did not completely abolish the immunogenicity of cancer cells responding to phox‐ER stress meaning thereby that (1) either a minor residual exposure/secretion of DAMPs regulated by these signalling molecules is sufficient for conferring a particular degree of immunogenicity or (2) there are additional yet‐to‐be‐described danger signals non‐dependent on these pathway components that contribute to phox‐ER stress‐induced immunogenicity.
In conclusion, this study shows that phox‐ER stress leads to the generation of the immunological and molecular hallmarks of immunogenic apoptosis in cancer cells. Our findings expand the set of experimental anticancer treatments that can induce immunogenic cell death by adding Hyp‐PDT. We also demonstrate for the first time that two DAMPs, ecto‐CRT and secreted ATP, can be ‘emitted’ in the ‘pre‐apoptotic’ phase of cell death through a common molecular pathway in which PERK, an ER stress sensor, is at the signalling core. This is the first report on two critical DAMPs following overlapping molecular pathways to reach the extracellular space. Moreover, our study suggests that the LRP1‐rich areas might be the elusive surface docking entities for ecto‐CRT on the dying cancer cell surface.
In a more general sense, an important conclusion that can be derived from our study is that the emission of key DAMPs, like ecto‐CRT and secreted ATP, by cancer cells can occur through mechanisms that are evidently stress specific. The dispensability of caspase signalling for the mobilization of DAMPs and immunogenic apoptosis induced by phox‐ER stress is also a novel observation. It implies that emission of danger signals by the stressed cancer cells is a phenomenon mediated by a separate ROS and ER stress‐mediated subroutine, which occurs in parallel to apoptosis induction. This is a premise that deserves to be substantiated in further investigations and which may have important implications for the development of new treatment modalities harnessing the immunogenicity of the cancer cells.
Materials and methods
Materials and reagents
Hypericin was prepared, purified, and stored as described previously (Buytaert et al, 2006). Z‐Val‐Ala‐Asp(OMe)‐fmk (zVAD‐fmk) was purchased from Bachem (Weil am Rhein, Germany). Latrunculin B (LanB) and 1,2‐bis(2‐aminophenoxy)ethane‐N,N,N′,N′‐tetracetate acetyloxy methylester (BAPTA‐AM) were purchased from Invitrogen (Carlsbad, CA, USA). Brefeldin A (BFA), l‐Histidine (l‐Hist), Mitoxantrone (MTX), Doxorubicin (DOXO), Nocodazole (Noco), and Wortmannin (Wort) were purchased from Sigma (St Louis, MO, USA). Methyl‐β‐cyclodextrin (MBC) was a kind gift from Prof. J Swinnen (Catholic University of Leuven, Belgium). Antibodies against ERp57, CHOP, P‐eIF2α, eIF2α, HSP90, caspase 3, Bip/GRP78, and PERK were purchased from Cell Signaling Technology (Danvers, MA, USA). Anti‐calnexin antibody was purchased from Stressgen (Victoria, BC, Canada). Anti‐calreticulin antibodies were purchased from Stressgen or Pierce. Rabbit polyclonal antibody (1704) recognizing the C‐terminus of the LRP1 protein has been described previously (Reekmans et al, 2010). Anti‐PI3K p110α antibody was purchased from Pierce. Anti‐caspase‐8 antibody was purchased from Alexis Biochemicals (San Diego, CA, USA). Anti‐Na+/K+ ATPase antibody was purchased from Novus Biologicals (Littleton, CO, USA). Anti‐FAS/CD95 (N‐18, M‐20, and C‐20), anti‐ICAM‐1, and anti‐HSP70 antibodies were purchased from Santa Cruz Biotech (Santa Cruz, CA, USA). Anti‐actin antibody was purchased from Sigma. Antibody against the KDEL sequence was purchased from Abcam (Cambridge, UK). Anti‐PARP antibody was purchased from BD Pharmingen (San Jose, CA, USA). Anti‐CD47 antibody was purchased from ImmunoTools (Friesoythe, Germany). Secondary antibodies conjugated to horseradish peroxidase were purchased from Cell Signaling Technology or Abcam.
Cell lines and induction of photo‐oxidative (phox)‐ER stress and/or immunogenic apoptosis
T24, CT26, HeLa, and MEF cells were cultured at 37°C under 5% CO2 in DMEM containing 4.5 g/l glucose and 0.11 g/l sodium pyruvate and supplemented with 2 mM glutamine, 100 units/ml penicillin, 100 μg/l streptomycin and 10% fetal bovine serum (referred to as normal culture medium hereafter). CHO cells were cultured in HAM‐F12 media supplemented with 2 mM glutamine, 100 units/ml penicillin, 100 μg/l streptomycin, and 10% fetal bovine serum. BAX/BAK DKO (double knock‐out) MEF cells overexpressing SERCA2 were maintained in culture medium containing 2 μg/ml puromycin (Invivogen, San Diego, CA, USA). Mf4/4 mouse macrophages were cultured in RPMI‐1640 medium supplemented with 10% fetal calf serum, 100 units/ml penicillin, 2 mM glutamine, 1 mM sodium pyruvate and 2 × 10−5 mM β‐mercaptoethanol. JAWSII mouse DC line was cultured in RPMI‐1640 medium supplemented with 10% fetal calf serum, 100 units/ml penicillin, 2 mM glutamine and 5 ng/ml granulocyte macrophage‐colony stimulating factor (GM‐CSF; PeproTech, Rocky Hill, NJ, USA).
For induction of immunogenic apoptosis, the cells were cultured in the presence of MTX (1 μM) or DOXO (25 μM). Phox‐ER stress was induced by Hypericin‐based PDT (Hyp‐PDT). For Hyp‐PDT (unless otherwise mentioned), T24 and CT26 cells were incubated with 150 nM Hypericin (for 16 h in normal culture medium), HeLa cells were incubated with 125 nM Hypericin (for 16 h in normal culture medium), CHO cells were incubated with 200 nM Hypericin (for 16 h in normal culture medium), while MEF cells were incubated with 200 nM Hypericin (for 2 h in serum‐free culture medium). Irradiation was performed as described previously (Vantieghem et al, 1998). Four Hyp‐PDT doses, based on the light fluence, were defined as low PDT dose (fluence=0.54 J/cm2), medium PDT dose (1.35 J/cm2), high PDT dose (2.16 J/cm2), and the highest PDT dose (2.70 J/cm2). For, Photofrin‐based PDT (PF‐PDT), the T24 cells were incubated with 10 μg/ml Photofrin (for 24 h in normal culture medium) and irradiated at a fluence of 0.48 J/cm2. Cells loaded with Hypericin or Photofrin were handled in either dark or subdued light (<1 μW/cm2). All the untreated or control (CNTR) sample conditions had Hypericin in absence of irradiation (i.e., absence of PDT treatment).
Generation of shRNA stable clones of CT26 cells
All the TRC1 shRNA clones were in lentiviral pLKO.1‐puro vector (Sigma‐Aldrich, St. Louis, MO, USA) and were obtained from the BCCM/LMBP Plasmid collection, Department of Biomedical Molecular Biology, Ghent University, Belgium (http://bccm.belspo.be/about/lmbp.php). An empty pLKO.1‐puro control vector was used as a control (CO‐shRNA) (BCCM/LMBP Plasmid collection). Three shRNAs targeted against each of the four murine mRNA types coding for proteins like LRP1, PI3K p110α, PERK, and caspase‐8, respectively, were used. Sequences of these shRNAs are mentioned in Supplementary Table S1. To generate lentivirus particles, HEK 293T cells were seeded in 25 cm2 flasks at 1.3 × 106 cells per 4 ml and transfected the following day by the calcium phosphate method with 4 μg of pLKO.1‐puro carrying the respective shRNAs or with empty pLKO.1‐puro. Each transfection also included 1.2 μg of a plasmid encoding VSV‐G (pMD2‐VSV‐G, Tronolab) and 2.6 μg of a plasmid encoding packaging proteins (pCMVdR8.9, Tronolab). After 6 h, the cells are washed with prewarmed PBS and 4 ml of fresh media was added. Twenty‐four hours after transfection, the cells were placed at 32°C for another 24 h. VSV‐G pseudotyped virus was collected 48 h after transfection, passed through 0.45 μm filters and then added to the exponentially growing CT26 cell cultures in the presence of 8 μg/ml of polybrene. Seven hours later a second infection was done. The cells were expanded and selected by puromycin treatment (9 μg/ml) for 3 days. Knockdown of LRP1, PI3K p110α, PERK, and caspase‐8 was confirmed by immunoblotting.
In‐vivo analysis of immune system priming in mice
All mice were maintained in pathogen‐free conditions and the experiments were performed according to the guidelines of the local Ethics Committee of Ghent University‐VIB and KU Leuven. CT26 cells were incubated with MTX (1 μM), tunicamycin (TUN, 65 μM; Sigma‐Aldrich) or exposed to the highest PDT dose of Hyp‐PDT. After a 24‐h recovery, 3 × 106 of these cells were injected subcutaneously (s.c.) in 200 μl of PBS into the left flank of 7‐week‐old female BALB/c mice from Janvier (Bio Services BV, The Netherlands). Immunization was done twice with a 10‐day interval. Control mice were injected with 200 μl PBS. Mice were then rechallenged with 5 × 105 live untreated CT26 cells in the other (right) flank 7 days after the second immunization. The ‘communication’ of the tumour antigenic memory to the adaptive immune system was studied by analysing the incidence of tumours at the rechallenge site (i.e., in the right flank of the mice). Hence, following the rechallenge, the mice were monitored every 5–6 days for the presence of tumours at the rechallenge site and the experiment was stopped as soon as the tumours in control mice became unmanageable, that is, either necrotic or capable of causing movement problems (about 20–30 days). Absence of tumours at the rechallenge site was taken as a sign of ‘priming’ of the adaptive immune system for the antigens derived from the treated/dying/dead CT26 cells.
Analysis of human DC maturation, NO, and cytokines
Human immature DCs (hu‐iDCs) were isolated and cultured as described (Ferreira et al, 2009). T24 cells exposed to high Hyp‐PDT treatment and AN (induced by one cycle of freeze thawing) were co‐incubated with hu‐iDCs at a ratio of 1:20 (hu‐iDCs:T24) for 24 h. Hu‐iDCs stimulated with 100 ng/ml of Escherichia coli‐derived LPS for 24 h (Sigma) were used as positive controls for DC maturation. After detachment and washing, the cells were stained with the following antibodies: FITC‐conjugated anti‐HLA‐DR (MHC II) (Invitrogen, Merelbeke, Belgium) and APC‐conjugated anti‐CD86 (Invitrogen, Merelbeke, Belgium) or FITC‐conjugated anti‐CD80 (Beckton & Dickinson, Mountain View, CA, USA) and APC‐conjugated anti‐CD83 (Invitrogen, Merelbeke, Belgium) according to manufacturer's instructions. Anti‐human IgG1 (Beckton & Dickinson) and anti‐human IgG2b (Invitrogen, Merelbeke, Belgium) antibodies were used as isotype controls. After the antibody staining, the cells were washed and analysed with a FACSCalibur flow cytometer (Beckton & Dickinson). The conditioned co‐culture media (CCM) derived from these hu‐iDC and T24 cell co‐incubation experiments were collected and stored for further analysis. NO in CCM was quantified by Griess assay (Becker et al, 2000). Immunoreactive levels of human IL‐1β (MPXHCYTO‐60K‐04) and IL‐10 (MPXHCYTO‐60K‐04) were measured in the CCM by using Milliplex human cytokines (Merck Millipore, Billerica, MA, USA). The samples were prepared according to manufacturers’ instructions and analysed on Bio‐Plex 200 Systems (Bio‐Rad, Hercules, CA, USA).
The cells were treated as indicated. Extracellular ATP was measured in the conditioned (serum‐free) media and intracellular ATP was determined after saponin‐based lysis. We used an ATP Bioluminescent assay kit (Sigma) based on luciferin‐luciferase conversion, following manufacturer's instructions. Bioluminescence was assessed by optical top reading via FlexStation 3 microplate reader (Molecular Devices Inc., Sunnyvale, CA, USA).
Bioinformatics and statistical analysis
Protein–protein binding interaction networks were generated using the STRING database (http://string-db.org/). Both predicted interactions and interactions supported by biochemical evidence or databases (including Reactome and Kyoto Encyclopedia of Genes and Genomes) were considered.
Data are presented in fold changes, absolute concentrations or percentages with mean±s.d. or mean±s.e.m. indicated in figure legends. All statistical analyses were performed using either Prism software (GraphPad Software, USA) or GraphPad QuickCalcs online software (http://www.graphpad.com/quickcalcs/index.cfm). Student's t‐test was used for statistical analysis with significance level set at P<0.05.
Supplementary data are available at The EMBO Journal Online (http://www.embojournal.org).
Conflict of Interest
The authors declare that they have no conflict of interest.
We would like to thank Amin Bredan for excellent editorial assistance. We acknowledge the help of Dr Raf Ponsaerts (KU Leuven, Leuven, Belgium) with ATP measurements and Dr Johan Swinnen for kindly providing us with reagents. We thank Dr Peter Carmeliet (Vesalius Research Center, VIB, Leuven, Belgium) for the CT26 cells and Dr Marek Michalak (University of Alberta, Alberta, Canada) for the CRT+/+ and CRT−/− MEF cells. This work was supported by a project from the Fund for Scientific Research Flanders (FWO‐Vlaanderen, G.0728.10 to PA and DVK). Research in Agostinis' group is supported by grants from the KU Leuven (GOA/11/009). and FWO‐Vlaanderen (G.0661.09). This paper presents research results of the IAP6/18, funded by the Interuniversity Attraction Poles Programme, initiated by the Belgian State, Science Policy Office. NR is a postdoctoral fellow supported by F.R.S‐FNRS (grant F/5/4/5‐MCF/KP). DVK is a postdoctoral fellow and AK is a doctoral fellow, both paid by fellowships from FWO‐Vlaanderen. Research in Vandenabeele's group is supported by VIB, Ghent University (GROUP‐ID consortium of the UGent MRP initiative), FWO‐Vlaanderen (G.0875.11 and G.0973.11), Federal Research Program (IAP 6/18), European Research Program FP6 ApopTrain (MRTN‐CT‐035624), FP7 Apo‐Sys 200767, and the Euregional PACTII. PV holds a Methusalem grant (BOF09/01M00709) from the Flemish Government. MF and JG are supported by Ministry of Science and Higher education grant N N401 037138 European Regional Development Fund through Innovative Economy grant POIG.01.01.02‐00‐008/08. MF and JG are members of TEAM Programme co‐financed by the Foundation for Polish Science and the EU European Regional Development Fund. JG is a recipient of the Mistrz Award from the Foundation for Polish Science. GBF is supported by a postdoctoral fellowship (FWO) and CM is supported by a clinical fellowship (FWO). We thank Jan Piessens (PA's lab), Liesbeth Heyndrickx (PV's lab), Vik Van Duppen (SCIL, Flow cytometry core), and Christine Michiels (WA's lab) for technical support. We acknowledge ‘The Hercules Foundation’ for supporting access to RNAi collections and associated facilities (grant AUGE/09/040 to PV) and for the Nikon A1R confocal microscope (AKUL/09/037 to WA). Some of the figures were produced using Servier Medical Art (http://www.servier.com), for which the authors would like to acknowledge Servier. Research in Roebroek's group is supported by grants from the KU Leuven (GOA/12/016) and FWO‐Vlaanderen (G.0529.08 and G.0689.10). WA is supported by VIB and KU Leuven (GOA/11/009).
Author contributions: ADG contributed substantially to the study design, acquisition of most of the data as well as analysis/interpretation of data. Played a major role in drafting of the manuscript. DVK contributed to study design, construction of shRNA constructs, and their stable transduction, acquisition of (mainly in vivo) data, analysis of inflammatory profile of APCs and analysis/interpretation of data. Assisted in critical revising of the manuscript. TV contributed to acquisition of in‐vitro ER stress data and optimization of surface biotinylation protocol. GBF and CM contributed towards isolation and differentiation of hu‐iDCs. TM and PW contributed towards in‐vivo data acquisition and design of in‐vivo experiments. AK contributed towards the in‐vivo experiments and mice handling. NR contributed towards microscopic data acquisition and protocols. MF contributed towards acquisition of Photofrin‐PDT associated data. AJMR contributed towards making of tools associated with the LRP1/CD91 analysis. WA contributed towards exocytosis/secretory pathway data analysis. JG contributed towards study design and assisted in critical revising of the manuscript. PV contributed towards study design and assisted in critical revising of the manuscript. PA played a substantially major role in conception as well as design of the study, data analysis/interpretation and drafting as well as critical revising of the manuscript.
- Copyright © 2012 European Molecular Biology Organization